Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom

Assaf Chalid
* ,
Timothy Illidge
ORCID logo ,
Nathalie Waser
,
Mary He
,
Tina Li
,
Athanasios Zomas
,
Nawal Bentennakhil
,
Meredith Little
* ,
Pablo L. Ortiz-Romero
,
Nicola Pimpinelli
,
Mehul Dalal
,
Martine Bagot
Version 1 : Received: 20 October 2023 / Approved: 20 October 2023 / Online: 20 October 2023 (12:08:51 CEST)

A peer-reviewed article of this Preprint also exists.

Assaf, C.; Illidge, T.M.; Waser, N.; He, M.; Li, T.; Zomas, A.; Bent-Ennakhil, N.; Little, M.; Ortiz-Romero, P.L.; Pimpinelli, N.; Dalal, M.; Bagot, M. A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/ Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom. Cancers 2023, 15, 5669. Assaf, C.; Illidge, T.M.; Waser, N.; He, M.; Li, T.; Zomas, A.; Bent-Ennakhil, N.; Little, M.; Ortiz-Romero, P.L.; Pimpinelli, N.; Dalal, M.; Bagot, M. A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/ Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom. Cancers 2023, 15, 5669.

Abstract

(1) Background: Most patients with mycosis fungoides (MF), a form of cutaneous T-cell lym-phoma (CTCL), develop relapsed/refractory (R/R) disease following front-line systemic therapy. This report describes treatment patterns and outcomes from the subpopulation with R/R MF. (2) Methods: This observational, retrospective, cohort study analysed patient records (1984–2016) from 27 clinical sites in Eurpe. Outcomes included treatments received, response to first-, second- and third-line treatment, overall survival (OS), and progression-free survival (PFS). (3) Results: Of 104 patients with MF, 100 received second-line and 61 received third-line therapy. Median (range) times from start of first-line therapy to first R/R MF and from first to second R/R MF were 11.2 (0.3–166.5) and 13.5 (0.0–174.6) months, respectively. Second-and third-line treatment options varied and comprised systemic therapies (85% and 79% of patients, respectively), radio-therapy (32% and 34%, respectively) and topical therapies (48% and 36%, respectively). Median (95% confidence interval [CI]) OS from the diagnosis of first R/R MF was 11.5 (6.5–not reached [NR]) years and was higher with non-chemotherapy (NR) versus chemotherapy (6.5 years); es-timated median PFS (95% CI) from the time of first R/R MF was 1.3 (1.0–2.1) years. (4) Conclu-sion: High rates of R/R disease were observed after second- and third-line treatments in this re-al-world cohort, with longer median OS in patients receiving non-chemotherapy versus chemo-therapy. Following the standard management of MF and using recently approved targeted therapies can help improve patient outcomes in advanced-stage MF.

Keywords

mycosis fungoides; relapsed/refractory; treatment patterns; Europe; real-world data; observational study; overall survival; progression-free survival

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.